{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:06:02Z","timestamp":1771052762503,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.leukres.2025.108152","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:09:43Z","timestamp":1765901383000},"page":"108152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical characteristics, treatment pathway and resource utilisation for patients with chronic lymphocytic leukaemia: A multicentre retrospective study"],"prefix":"10.1016","volume":"160","author":[{"given":"Ahmad","family":"Alhuraiji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Alhejazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9754-0182","authenticated-orcid":false,"given":"Bhausaheb","family":"Bagal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chee Yen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efreen","family":"Monta\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2351-8158","authenticated-orcid":false,"given":"Macarena","family":"Roa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Pavlovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Samra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0772-869X","authenticated-orcid":false,"given":"Shang-Ju","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veena","family":"Selvaratnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Elsayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amgad","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Pushpalata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akemi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2025.108152_bib1","first-page":"1","article-title":"Chronic Lymphocytic Leukemia","author":"Chennamadhavuni","year":"2023","journal-title":"StatPearls NCBI Bookshelf"},{"key":"10.1016\/j.leukres.2025.108152_bib2","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.leukres.2025.108152_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/437971","article-title":"Cancer incidence in egypt: results of the national population-based cancer registry program","volume":"2014","author":"Ibrahim","year":"2014","journal-title":"J. Cancer Epidemiol."},{"key":"10.1016\/j.leukres.2025.108152_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106668","article-title":"Chronic lymphocytic leukemia in a young population","volume":"110","author":"Alshemmari","year":"2021","journal-title":"Leuk. Res"},{"key":"10.1016\/j.leukres.2025.108152_bib5","series-title":"Key Statistics for Chronic Lymphocytic Leukemia","author":"The American Cancer Society","year":"2024"},{"key":"10.1016\/j.leukres.2025.108152_bib6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.critrevonc.2016.06.003","article-title":"Chronic lymphocytic leukaemia","volume":"104","author":"Scarf\u00f2","year":"2016","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.leukres.2025.108152_bib7","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet (Lond. Engl. )"},{"key":"10.1016\/j.leukres.2025.108152_bib8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1080\/16078454.2020.1749473","article-title":"Up to half of patients diagnosed with chronic lymphocytic leukemia in M\u00e9xico may not require treatment","volume":"25","author":"Cruz-Mora","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.leukres.2025.108152_bib9","first-page":"1","article-title":"Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study","volume":"5","author":"Tietsche de Moraes Hungria","year":"2019","journal-title":"J. Glob. Oncol."},{"key":"10.1016\/j.leukres.2025.108152_bib10","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1186\/s12885-024-12343-1","article-title":"Prognostic impact of chronic lymphocytic leukemia comorbidity index in a young population: a real-world evidence study of a national gulf region cohort","volume":"24","author":"Alshemmari","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.leukres.2025.108152_bib11","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01054-w","article-title":"Current and future treatment strategies in chronic lymphocytic leukemia","volume":"14","author":"Patel","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2025.108152_bib12","article-title":"Chronic lymphocytic leukemia treatment algorithm 2022","volume":"12","author":"Hampel","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2025.108152_bib13","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1200\/GO.20.00032","article-title":"Chronic Lymphocytic Leukemia: Real-World Data From India","author":"Tejaswi","year":"2020","journal-title":"JCO Glob. Oncol."},{"key":"10.1016\/j.leukres.2025.108152_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s44228-023-00035-9","article-title":"Clinical and Cytogenetic Characterization, and Outcome of Chronic Lymphocytic Leukemia Patients in a Single Tertiary Center in Saudi Arabia","volume":"5","author":"Al Mugairi","year":"2023","journal-title":"Clin. Hematol. Int."},{"key":"10.1016\/j.leukres.2025.108152_bib15","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J. Surg."},{"key":"10.1016\/j.leukres.2025.108152_bib16","doi-asserted-by":"crossref","first-page":"212.e1","DOI":"10.1016\/j.jclinepi.2005.12.021","article-title":"Abbreviated guidelines for scoring the Cumulative Illness Rating Scale (CIRS) in family practice","volume":"60","author":"Hudon","year":"2007","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.leukres.2025.108152_bib17","first-page":"41","article-title":"The Treatment of Chronic Lymphatic Leukemia","volume":"116","author":"Tresckow","year":"2019","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.leukres.2025.108152_bib18","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.108152_bib19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.21315\/mjms2018.25.4.12","article-title":"Sample Size Guidelines for Logistic Regression from Observational Studies with Large Population: Emphasis on the Accuracy Between Statistics and Parameters Based on Real Life Clinical Data","volume":"25","author":"Bujang","year":"2018","journal-title":"Malays. J. Med Sci."},{"key":"10.1016\/j.leukres.2025.108152_bib20","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1080\/10428194.2020.1869966","article-title":"Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia","volume":"62","author":"Hampel","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2025.108152_bib21","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.108152_bib22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.leukres.2019.02.005","article-title":"Improving risk-stratification of patients with chronic lymphocytic leukemia using multivariate patient similarity networks","volume":"79","author":"Turcsanyi","year":"2019","journal-title":"Leuk. Res"},{"key":"10.1016\/j.leukres.2025.108152_bib23","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2025.108152_bib24","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/jha2.444","article-title":"Lower access to risk stratification tests and drugs, and worse survival of chronic lymphocytic leukaemia patients treated in public as compared to private hospitals in Brazil: A retrospective analysis of the Brazilian registry of chronic lymphocytic leuka","volume":"3","author":"Pfister","year":"2022","journal-title":"eJHaem"},{"key":"10.1016\/j.leukres.2025.108152_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e19512","article-title":"Real-world data of lebanese patients with chronic lymphocytic leukemia","volume":"40","author":"Nasr","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.108152_bib26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.clml.2019.10.009","article-title":"Prognostic testing and treatment patterns in chronic lymphocytic leukemia in the era of novel targeted therapies: results from the informCLL registry","author":"Mato","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2025.108152_bib27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cncr.31738","article-title":"Real-world testing and treatment patterns in chronic lymphocytic leukemia: a SEER patterns of care analysis","volume":"125","author":"Seymour","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2025.108152_bib28","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-017-0448-2","article-title":"Current treatment of chronic lymphocytic leukemia","volume":"18","author":"Jamroziak","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.leukres.2025.108152_bib29","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3324\/haematol.2016.157552","article-title":"Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications","volume":"102","author":"Wu","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2025.108152_bib30","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1016\/j.clml.2021.07.022","article-title":"Real-world characteristics and outcome of patients treated with single-agent ibrutinib for chronic lymphocytic leukemia in Spain (IBRORS-LLC Study)","volume":"21","author":"Abrisqueta","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2025.108152_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164047","article-title":"Real-world evidence on the clinical characteristics and management of patients with chronic lymphocytic leukemia in Spain using natural language processing: the SRealCLL study","volume":"15","author":"Loscertales","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.leukres.2025.108152_bib32","doi-asserted-by":"crossref","first-page":"E360","DOI":"10.1093\/oncolo\/oyad324","article-title":"Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US","volume":"29","author":"Yang","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2025.108152_bib33","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1007\/s12325-020-01350-w","article-title":"Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study","volume":"37","author":"Kabadi","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.leukres.2025.108152_bib34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11899-021-00637-1","article-title":"Frontline Treatment for Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL): Targeted Therapy vs. Chemoimmunotherapy","volume":"16","author":"Small","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.leukres.2025.108152_bib35","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and Treatment of Chronic Lymphocytic Leukemia","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.leukres.2025.108152_bib36","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1158\/1078-0432.CCR-21-1237","article-title":"Recognizing Unmet Need in the Era of Targeted Therapy for CLL\/SLL: \u2018What\u2019s Past Is Prologue\u2019 (Shakespeare)","volume":"28","author":"Mato","year":"2022","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.leukres.2025.108152_bib37","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.108152_bib38","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625006423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625006423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T05:22:37Z","timestamp":1767936157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625006423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"alternative-id":["S0145212625006423"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108152","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics, treatment pathway and resource utilisation for patients with chronic lymphocytic leukaemia: A multicentre retrospective study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.108152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108152"}}